SAN DIEGO, May 5, 2011 /PRNewswire/ — Ridge Diagnostics,
Inc., a neurodiagnostic company, announced that Lonna J.
Williams, CEO will speak at the 6th Annual Neurotech Investing and
Partnering Conference to be held in San Francisco, CA at the St.
Regis Hotel on May 9th and 10th.
Ms. Williams, a clinical diagnostics industry veteran, will
participate on a panel entitled “Next Generation Psychiatry” lead
by Dr. Manuel Lopez-Figueroa, Vice President, Bay City Capital. The
panel will discuss the most promising next generation diagnostics,
devices and treatments for neuropsychiatric disorders such as
depression, schizophrenia, anxiety, addiction and others.
Ridge Diagnostics develops and sells blood tests which aid in
the diagnosis and management of clinical depression or Major
Depressive Disorder. For the first time, a blood test
provides clinicians and patients with objective, biologically
based, diagnostic information to manage and treat this disorder.
Blood test results are intended to augment the current
tools used for neuropsychiatric diagnosis and patient management.
Additional tests are in development for antidepressant
efficacy monitoring and adolescent depression.
Ridge Diagnostics, Inc. Ridge Diagnostics is a
neurodiagnostic company developing and marketing blood-based tests
to diagnose and monitor neuropsychiatric disorders. Ridge has
commercialized the first-in-class, proprietary blood test for the
diagnosis and treatment monitoring of Major Depressive Disorder
(MDD). The portfolio of neurodiagnostic blood tests are
based on a proprietary Human Biomarker Library and Hyper-Mapping
technology. The testing services are provided by the Ridge
owned CLIA laboratory. The company is located in San Diego, CA and
Research Triangle Park, NC. www.ridgedx.com
Neurotech Investing and Partnering Conference. The